Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin Lymphoma and in Hodgkin Lymphoma survivors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Real-World Outcomes for 205 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  • Hugo Vachon
  • Justyna Mierzynska
  • Mekdes Taye
  • Madeline Pe
  • Corneel Coens
  • Francesca Martinelli
  • Catherine Fortpied
  • Henning-Hans Flechtner
  • Maja Vestmoe Maraldo
  • Martin Hutchings
  • Paul Meijnders
  • Berthe Aleman
  • Pieternella Lugtenburg
  • Michele Spina
  • Marc André
  • Mark Hertzberg
  • Javier Briones
  • Andrew Bottomley
  • EORTC Quality of Life Group, Lymphoma Group
Vis graf over relationer

OBJECTIVES: To provide reference values for the European Organisation for Treatment and Research of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) in advanced-stage Hodgkin lymphoma (HL) patients and 5-year HL survivors. The QLQ-C30 is the most widely used cancer-specific questionnaire to assess Health-Related Quality of Life (HRQoL).

METHODS: The EORTC database was searched to identify HL RCTs in which patients' and survivors' HRQoL was assessed by the QLQ-C30. HRQoL mean scores were calculated and stratified by age and gender. Minimal important differences were used to assess the clinical relevance of the findings. Data from one RCT with HRQoL scores available at baseline (n = 343) and four RCTs with HRQoL scores available at follow-up (n = 1665) were analyzed.

RESULTS: Patients reported worse HRQoL scores than survivors across most functioning scales and symptoms' scales. These scores varied as a function of gender but not age. Survivors' HRQoL reports were comparable to the ones of the general population.

CONCLUSIONS: These values provide an assessment framework for the comparison and interpretation of QLQ-C30 scores in advanced-stage HL. Our findings suggest that although HL patients' HRQoL scores are worse than the general population, HRQoL scores may normalize over long-term survival.

TidsskriftEuropean Journal of Haematology
Udgave nummer5
Sider (fra-til)697-707
Antal sider11
StatusUdgivet - maj 2021

ID: 62111053